Adverum Biotechnologies Inc is a US-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company has primarily generated revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durability with treatment response, reduce the treatment burden of frequent anti-vascular endothelial growth factor (anti-VEGF) injections, and improve real-world vision outcomes for patients.
If you want not to miss ideas like this one,๐ฏ subscribe and press a thumb up! ๐ Have a question? Don't be shy to ask! ๐ค Interested to study how to analyze charts, follow me!
If you want not to miss ideas like this one,๐ฏ subscribe and press a thumb up! ๐ Have a question? Don't be shy to ask! ๐ค Interested to study how to analyze charts, follow me!
| disciplined | patient | humble | consistently profitable |
๋ฉด์ฑ ์ฌํญ
ํด๋น ์ ๋ณด์ ๊ฒ์๋ฌผ์ ๊ธ์ต, ํฌ์, ํธ๋ ์ด๋ฉ ๋๋ ๊ธฐํ ์ ํ์ ์กฐ์ธ์ด๋ ๊ถ์ฅ ์ฌํญ์ผ๋ก ๊ฐ์ฃผ๋์ง ์์ผ๋ฉฐ, ํธ๋ ์ด๋ฉ๋ทฐ์์ ์ ๊ณตํ๊ฑฐ๋ ๋ณด์ฆํ๋ ๊ฒ์ด ์๋๋๋ค. ์์ธํ ๋ด์ฉ์ ์ด์ฉ ์ฝ๊ด์ ์ฐธ์กฐํ์ธ์.
| disciplined | patient | humble | consistently profitable |
๋ฉด์ฑ ์ฌํญ
ํด๋น ์ ๋ณด์ ๊ฒ์๋ฌผ์ ๊ธ์ต, ํฌ์, ํธ๋ ์ด๋ฉ ๋๋ ๊ธฐํ ์ ํ์ ์กฐ์ธ์ด๋ ๊ถ์ฅ ์ฌํญ์ผ๋ก ๊ฐ์ฃผ๋์ง ์์ผ๋ฉฐ, ํธ๋ ์ด๋ฉ๋ทฐ์์ ์ ๊ณตํ๊ฑฐ๋ ๋ณด์ฆํ๋ ๊ฒ์ด ์๋๋๋ค. ์์ธํ ๋ด์ฉ์ ์ด์ฉ ์ฝ๊ด์ ์ฐธ์กฐํ์ธ์.
